ARQT
Arcutis Biotherapeutics, Inc. NASDAQ Listed Jan 31, 2020$20.66
Mkt Cap $2.6B
52w Low $12.72
41.7% of range
52w High $31.77
50d MA $23.70
200d MA $22.98
P/E (TTM)
-179.6x
EV/EBITDA
1475.1x
P/B
15.7x
Debt/Equity
0.0x
ROE
-8.5%
P/FCF
-585.5x
RSI (14)
—
ATR (14)
—
Beta
1.77
50d MA
$23.70
200d MA
$22.98
Avg Volume
1.3M
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
3027 Townsgate Road · Westlake Village, CA 91361 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.02 | -0.09 | -350.0% | 24.17 | -5.6% | -14.5% | — | — | — | — | — |
| Feb 25, 2026 | AMC | 0.03 | 0.13 | +333.3% | 27.01 | +2.5% | +5.8% | -5.6% | -8.2% | -4.7% | +2.2% | — |
| Oct 28, 2025 | AMC | -0.10 | 0.06 | +160.0% | 24.95 | +3.6% | +1.4% | -1.5% | +1.6% | -2.2% | -3.0% | — |
| Aug 6, 2025 | AMC | -0.18 | -0.13 | +27.8% | 15.36 | +5.9% | -8.1% | +4.6% | -3.9% | +3.9% | +6.0% | — |
| May 6, 2025 | AMC | -0.21 | -0.20 | +4.8% | 14.32 | -0.6% | -4.3% | -1.3% | +0.1% | +6.4% | -4.0% | — |
| Feb 25, 2025 | AMC | -0.28 | -0.09 | +67.9% | 12.20 | +13.5% | +8.4% | -3.2% | +7.0% | -6.3% | +4.4% | — |
| Nov 6, 2024 | AMC | -0.42 | -0.33 | +21.4% | 9.66 | +6.6% | +7.7% | +4.0% | +0.2% | -5.4% | +2.1% | — |
| Aug 14, 2024 | AMC | -0.48 | -0.42 | +12.5% | 9.58 | -4.0% | -11.3% | -0.1% | +1.9% | -2.7% | -0.9% | — |
| May 14, 2024 | AMC | -0.60 | -0.32 | +46.7% | 8.13 | +15.9% | +13.7% | -1.3% | +0.9% | +1.6% | +1.4% | — |
| Feb 27, 2024 | AMC | -0.65 | -0.72 | -10.8% | 10.63 | +0.3% | -2.1% | -1.2% | +14.5% | -7.0% | -0.5% | — |
| Nov 3, 2023 | AMC | -0.90 | -0.73 | +18.9% | 2.44 | +2.5% | -4.1% | +0.4% | -6.4% | -9.1% | -4.7% | — |
| Aug 8, 2023 | AMC | -1.22 | -1.16 | +4.9% | 9.83 | +5.1% | -4.5% | -1.2% | -3.4% | -3.0% | -2.5% | — |
| May 9, 2023 | AMC | -1.30 | -1.31 | -0.8% | 14.82 | -0.7% | -18.8% | -10.0% | -6.9% | +2.2% | -3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2 | Mizuho | Maintains | Outperform → Outperform | — | $26.97 | $25.94 | -3.8% | -8.2% | -4.7% | +2.2% | -0.6% | +0.1% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $28.57 | $27.95 | -2.2% | -5.6% | -8.2% | -4.7% | +2.2% | -0.6% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $27.01 | $27.69 | +2.5% | +5.8% | -5.6% | -8.2% | -4.7% | +2.2% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $27.01 | $27.69 | +2.5% | +5.8% | -5.6% | -8.2% | -4.7% | +2.2% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.01 | $27.69 | +2.5% | +5.8% | -5.6% | -8.2% | -4.7% | +2.2% |
| Jan 26 | Needham | Maintains | Buy → Buy | — | $26.20 | $25.80 | -1.5% | +0.5% | +0.0% | -3.3% | +1.1% | -1.4% |
| Nov 28 | Mizuho | Maintains | Outperform → Outperform | — | $30.96 | $31.27 | +1.0% | -1.0% | -0.9% | -3.1% | +1.8% | +4.0% |
| Oct 30 | Goldman Sachs | Maintains | Neutral → Neutral | — | $25.29 | $25.89 | +2.4% | -1.5% | +1.6% | -2.2% | -3.0% | +1.5% |
| Oct 28 | Needham | Maintains | Buy → Buy | — | $19.64 | $22.50 | +14.6% | +27.0% | +1.4% | -1.5% | +1.6% | -2.2% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $15.36 | $16.27 | +5.9% | -8.1% | +4.6% | -3.9% | +3.9% | +6.0% |
| May 23 | Needham | Maintains | Buy → Buy | — | $13.66 | $13.49 | -1.2% | +2.3% | +1.1% | -4.0% | +0.7% | -4.6% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $13.29 | $12.87 | -3.2% | +9.6% | -7.8% | -6.3% | +2.8% | +1.9% |
| Apr 3 | Guggenheim | Maintains | Buy → Buy | — | $16.60 | $15.95 | -3.9% | -2.7% | -8.8% | -2.9% | -7.1% | +9.6% |
| Apr 3 | Needham | Maintains | Buy → Buy | — | $16.60 | $15.95 | -3.9% | -2.7% | -8.8% | -2.9% | -7.1% | +9.6% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.60 | $15.95 | -3.9% | -2.7% | -8.8% | -2.9% | -7.1% | +9.6% |
| Mar 11 | Jefferies | Maintains | Buy → Buy | — | $14.38 | $14.39 | +0.1% | +7.7% | -2.1% | -2.3% | -1.3% | +12.3% |
| Feb 27 | Goldman Sachs | Maintains | Neutral → Neutral | — | $13.22 | $13.24 | +0.2% | -3.2% | +7.0% | -6.3% | +4.4% | +10.3% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.20 | $13.85 | +13.5% | +8.4% | -3.2% | +7.0% | -6.3% | +4.4% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $12.20 | $13.85 | +13.5% | +8.4% | -3.2% | +7.0% | -6.3% | +4.4% |
| Feb 26 | Mizuho | Maintains | Outperform → Outperform | — | $12.20 | $13.85 | +13.5% | +8.4% | -3.2% | +7.0% | -6.3% | +4.4% |
| Feb 24 | Guggenheim | Maintains | Buy → Buy | — | $13.02 | $12.96 | -0.5% | -4.8% | -1.5% | +8.4% | -3.2% | +7.0% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $11.61 | $11.75 | +1.2% | -0.2% | -1.6% | +15.9% | -6.8% | +3.8% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.81 | $14.99 | +8.5% | -1.3% | -2.6% | +4.8% | -1.2% | -7.8% |
| Jan 7 | Mizuho | Maintains | Outperform → Outperform | — | $14.71 | $15.13 | +2.9% | +7.1% | -3.1% | -9.6% | -1.3% | -2.6% |
| Dec 17 | Needham | Maintains | Buy → Buy | — | $13.57 | $13.45 | -0.9% | +9.5% | -9.8% | +5.3% | +6.2% | -0.1% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $9.66 | $10.30 | +6.6% | +7.7% | +4.0% | +0.2% | -5.4% | +2.1% |
| Aug 15 | Needham | Maintains | Buy → Buy | — | $9.58 | $9.20 | -4.0% | -11.3% | -0.1% | +1.9% | -2.7% | -0.9% |
| Jul 30 | Needham | Maintains | Buy → Buy | — | $9.57 | $9.68 | +1.1% | +0.6% | +4.6% | -5.9% | -2.4% | -1.6% |
| Jul 10 | Needham | Maintains | Buy → Buy | — | $10.02 | $10.32 | +3.0% | -2.1% | +9.4% | -1.0% | +1.4% | -0.9% |
| May 15 | Needham | Maintains | Buy → Buy | — | $8.13 | $9.42 | +15.9% | +13.7% | -1.3% | +0.9% | +1.6% | +1.4% |
| May 15 | Mizuho | Maintains | Buy → Buy | — | $8.13 | $9.42 | +15.9% | +13.7% | -1.3% | +0.9% | +1.6% | +1.4% |
| Apr 12 | Needham | Maintains | Buy → Buy | — | $11.88 | $11.77 | -0.9% | -14.1% | -1.1% | +0.1% | +1.5% | -7.8% |
| Feb 28 | Mizuho | Maintains | Buy → Buy | — | $10.63 | $10.66 | +0.3% | -2.1% | -1.2% | +14.5% | -7.0% | -0.5% |
| Feb 28 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.63 | $10.66 | +0.3% | -2.1% | -1.2% | +14.5% | -7.0% | -0.5% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $10.63 | $10.66 | +0.3% | -2.1% | -1.2% | +14.5% | -7.0% | -0.5% |
| Feb 23 | Mizuho | Maintains | Buy → Buy | — | $9.62 | $9.88 | +2.7% | +0.6% | +0.1% | +9.7% | -2.1% | -1.2% |
| Jan 3 | Mizuho | Upgrade | Neutral → Buy | — | $3.43 | $3.67 | +7.0% | +14.0% | +3.3% | -8.2% | +9.2% | +0.0% |
| Jan 2 | Mizuho | Upgrade | Neutral → Buy | — | $3.23 | $3.17 | -1.9% | +6.2% | +14.0% | +3.3% | -8.2% | +9.2% |
| Nov 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1.91 | $1.87 | -1.8% | +10.8% | +3.3% | -4.6% | -6.2% | +4.6% |
| Nov 8 | JonesTrading | Downgrade | Buy → Hold | — | $2.35 | $2.37 | +0.9% | -6.4% | -9.1% | -4.8% | +10.8% | +3.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.44 | $2.50 | +2.5% | -4.1% | +0.4% | -6.4% | -9.1% | -4.7% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $2.44 | $2.50 | +2.5% | -4.1% | +0.4% | -6.4% | -9.1% | -4.7% |
| Oct 27 | Mizuho | Downgrade | Buy → Neutral | — | $2.37 | $2.40 | +1.3% | -1.5% | -1.5% | -2.2% | +0.4% | -1.8% |
| Oct 13 | Goldman Sachs | Downgrade | Buy → Neutral | — | $3.88 | $3.53 | -9.0% | +0.0% | -3.2% | +2.5% | -16.1% | -6.2% |
| Sep 25 | Mizuho | Maintains | Buy → Buy | — | $5.38 | $5.52 | +2.6% | +7.4% | +0.9% | -4.3% | -0.7% | -4.2% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.28 | $7.27 | -0.1% | +3.1% | +0.3% | -0.3% | +3.2% | +3.6% |
| Aug 10 | Needham | Maintains | Buy → Buy | — | $9.39 | $9.40 | +0.1% | -1.2% | -3.4% | -3.0% | -2.5% | -3.1% |
| Aug 9 | TD Cowen | Maintains | Outperform → Outperform | — | $9.83 | $10.33 | +5.1% | -4.5% | -1.2% | -3.4% | -3.0% | -2.5% |
| Jul 18 | Needham | Maintains | Buy → Buy | — | $10.98 | $10.96 | -0.2% | -3.6% | -1.8% | -0.4% | +1.3% | -1.8% |
| Jun 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.47 | $8.50 | +0.4% | +1.8% | -3.4% | +14.4% | -8.2% | +6.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Burnett PatrickOff | See Remarks | Sell | 684 | $23.61 | $16K | 120,466 | -14.52% | — |
| May 4, 2026 | Vairavan LathaOff | SVP Chief Financial Officer | Sell | 1,341 | $23.61 | $32K | 86,413 | -14.52% | — |
| May 4, 2026 | Matsuda MasaruOff | See Remarks | Sell | 884 | $23.61 | $21K | 126,689 | -14.52% | — |
| May 4, 2026 | Matsuda MasaruOff | See Remarks | Sell | 7,372 | $23.27 | $172K | 127,573 | -14.52% | — |
| May 4, 2026 | Watanabe ToddDir/Off | See Remarks | Sell | 3,172 | $23.61 | $75K | 720,755 | -14.52% | — |
| May 1, 2026 | Welgus Howard G.Dir | — | Sell | 7,144 | $22.99 | $164K | 32,600 | +3.20% | — |
8-K · 5.02
!!! Very High
MBX Biosciences, Inc. -- 8-K 5.02: Executive Change
MBX Biosciences replaced CFO Richard Bartram with interim CFO John Smither, effective March 16, 2026, signaling potential leadership transition during a critical period for the company.
Feb 27
8-K
Arcutis Biotherapeutics, Inc. -- 8-K Filing
Arcutis Biotherapeutics achieved over 90% year-over-year net product revenue growth in 2025, driven by strong ZORYVE demand and successful multi-product launches in its immuno-dermatology focus area.
Feb 25
Data updated apr 24, 2026 7:00pm
· Source: massive.com